PFE vs JNJ Stock Comparison: AI Score, Valuation, Performance and Upside
Pfizer and Johnson & Johnson are both large-cap healthcare dividend companies managing major revenue transitions. Pfizer navigates the post-COVID revenue cliff while integrating Seagen's oncology portfolio. J&J navigates Stelara biosimilar pressure while growing Darzalex, Carvykti, and MedTech. J&J's diversification across pharma and devices provides more stability; Pfizer's COVID-era wealth is being redeployed into oncology with higher execution risk.
PFE vs JNJ is Pfizer managing post-COVID revenue normalization while building an oncology platform through Seagen ADC acquisition versus J&J's diversified pharma-plus-medical-device model with Darzalex/Carvykti growth offsetting Stelara biosimilar headwinds — both navigating patent cliff transitions with different pipeline replacement strategies.
JNJ holds the edge across 4 of 5 key metrics in this comparison. JNJ has delivered stronger 1-year price return (+55.02% vs +14.53%), though PFE has the better forward P/E setup (9.83x vs 21.78x for JNJ). JNJ leads on both revenue growth (6.60%) and operating margin (29.19%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies similar upside for both: +0.55% for PFE and +1.66% for JNJ.
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- prefer a potentially undervalued large-cap pharma recovery story — Pfizer's COVID revenue collapse has depressed the stock despite the Seagen oncology asset quality
- value ADC (antibody-drug conjugate) oncology exposure through Seagen's Padcev and other assets in the fastest-growing drug class in oncology
- want the highest current dividend yield among major pharma companies — Pfizer's yield expanded significantly as the stock declined post-COVID peak
- are comfortable with Seagen integration execution risk, ongoing COVID revenue normalization headwinds, and 2025–2028 patent cliff management uncertainty
- prefer diversified healthcare blue-chip with pharma + medical device combination providing revenue source diversification beyond single drug patent cycles
- value J&J's 60+ consecutive dividend increases — one of only a handful of companies to achieve Dividend King status with this level of dividend consistency
- want Darzalex and Carvykti oncology growth paired with MedTech procedure volume recovery as complementary growth drivers
- are comfortable with Stelara biosimilar revenue headwind, talc litigation overhang, and slower growth from a large, established base
| Metric | PFE | JNJ |
|---|---|---|
| AI scorei | 39.3 | 49.9 |
| AI ranki | #1256 | #553 |
| Latest closei | $27.66 | $269.99 |
| 1M returni | -2.05% | -1.25% |
| 6M returni | +0.91% | +13.63% |
| 1Y returni | +14.53% | +55.02% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | PFE | JNJ |
|---|---|---|
| 1Y ago | $11.45K (+14.5%) started 2025-09-18 | $15.5K (+55.0%) started 2025-09-18 |
| 5Y ago | $9.11K (-8.9%) started 2021-09-20 | $20.29K (+102.9%) started 2021-09-20 |
| 10Y ago | $19.57K (+95.7%) started 2016-09-19 | $37.68K (+276.8%) started 2016-09-19 |
Hypothetical — past performance does not guarantee future results.
| Metric | PFE | JNJ |
|---|---|---|
| Market capi | $162.16B | $645.95B |
| Trailing P/Ei | 37.43 | 31.06 |
| Forward P/Ei | 9.83 | 21.78 |
| Price/Salesi | 2.13 | 4.18 |
| EV/Revenuei | 3.36 | 6.88 |
| Analyst targeti | $28.61 | $272.50 |
| Target upsidei | +0.55% | +1.66% |
| Metric | PFE | JNJ |
|---|---|---|
| Revenue growthi | 2.60% | 6.60% |
| Earnings growthi | -10.10% | -0.90% |
| EPS growthi | -10.10% | -0.90% |
| FCF margini | +19.60% | +17.24% |
| Operating margini | 27.88% | 29.19% |
| Profit margini | 6.80% | 21.48% |
| ROIC proxyi | 5.01% | 25.74% |
| Return on equityi | 5.01% | 25.74% |
| Dividend yieldi | 6.05% | 2.00% |
| Payout ratioi | 226.32% | 60.79% |
| Dividend growth streaki | No increase yet | No increase yet |
| Betai | 0.30 | 0.23 |
| Debt/equityi | 74.25 | 57.71 |
| Current ratioi | 1.27 | 1.09 |
| Quick ratioi | 0.85 | 0.72 |
Over the past year, PFE and JNJ have moved weakly in the same direction (correlation of 0.30), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | PFE | JNJ |
|---|---|---|---|
| 1Y | Growthi | +14.53% | +55.02% |
| CAGRi | +14.54% | +55.07% | |
| Volatilityi | 23.60% | 19.04% | |
| Sharpe ratioi | 0.50 | 2.17 | |
| Sortino ratioi | 0.79 | 3.47 | |
| Max drawdowni | 17.09% | 10.96% | |
| Current drawdowni | 4.69% | 3.03% | |
| Avg drawdowni | 6.72% | 2.95% | |
| Ulcer Indexi | 7.92% | 4.12% | |
| Max daily dropi | 3.43% | 3.66% | |
| Max wkly dropi | 9.46% | 6.22% | |
| 5Y | Growthi | -25.10% | +82.43% |
| CAGRi | -5.62% | +12.79% | |
| Volatilityi | 25.40% | 17.60% | |
| Sharpe ratioi | -0.28 | 0.52 | |
| Sortino ratioi | -0.41 | 0.76 | |
| Max drawdowni | 58.96% | 18.41% | |
| Current drawdowni | 46.42% | 3.03% | |
| Avg drawdowni | 38.14% | 7.01% | |
| Ulcer Indexi | 41.46% | 8.57% | |
| Max daily dropi | 6.72% | 7.59% | |
| Max wkly dropi | 11.19% | 9.18% | |
| 10Y | Growthi | +25.36% | +189.90% |
| CAGRi | +2.29% | +11.23% | |
| Volatilityi | 24.08% | 18.84% | |
| Sharpe ratioi | 0.03 | 0.42 | |
| Sortino ratioi | 0.04 | 0.60 | |
| Max drawdowni | 58.96% | 27.37% | |
| Current drawdowni | 46.42% | 3.03% | |
| Avg drawdowni | 23.44% | 6.40% | |
| Ulcer Indexi | 30.34% | 7.97% | |
| Max daily dropi | 7.73% | 10.04% | |
| Max wkly dropi | 15.34% | 13.25% |
| Category | PFE | JNJ |
|---|---|---|
| Company | Pfizer Inc. | Johnson & Johnson |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Core business | Pfizer is one of the world's largest pharmaceutical companies, best known for developing the first approved COVID-19 mRNA vaccine (Comirnaty) with BioNTech and the COVID antiviral Paxlovid. Post-COVID revenue normalization has been Pfizer's defining challenge — COVID product revenues collapsed from $57B (2022) to much lower levels, requiring Pfizer to replace this revenue through acquisitions (Seagen oncology for $43B), internal pipeline, and continued brand drug sales. Pfizer's oncology, internal medicine, and vaccine portfolios form the non-COVID revenue base. | Johnson & Johnson operates Innovative Medicine (drugs: Darzalex, Stelara, Tremfya, Carvykti) and MedTech (surgical devices, orthopedics, cardiovascular equipment). J&J spun off its consumer health segment (Kenvue) in 2023 to focus on higher-margin pharma and medical devices. Unlike Pfizer's COVID revenue peak-and-decline story, J&J had more consistent revenue growth through the pandemic period and faces a different set of patent cliff challenges (Stelara biosimilars in 2025) with medical device business providing diversification. |
| Investor focus | Investors track non-COVID revenue growth trajectory, Seagen oncology pipeline integration and sales (Padcev, Adcetris, Tivdak), and Pfizer's cost reduction program ($4B+ savings target) improving profitability during the revenue transition. | Investors track Darzalex multiple myeloma revenue, Carvykti CAR-T cell therapy manufacturing expansion, MedTech procedure volume recovery, and Stelara biosimilar erosion management. |
- Seagen oncology acquisition added 4 commercial antibody-drug conjugates (ADCs) plus a clinical pipeline — ADCs are the fastest-growing oncology drug class and Pfizer is now among the top ADC manufacturers
- COVID mRNA platform knowledge and manufacturing infrastructure positions Pfizer for future pandemic preparedness contracts and respiratory vaccine development
- Deep oncology pipeline (Ibrance, Xtandi, Braftovi, Seagen portfolio) creates multiple shots on goal across cancer treatment areas
- Medical device business provides revenue diversification unavailable to pure pharma peers — procedure volumes grow with aging population regardless of drug patent cycles
- Darzalex is still growing with multiple myeloma market expansion — one of the strongest oncology franchise drugs in the world
- 60+ consecutive dividend increases: J&J's Dividend King status makes it the standard healthcare income holding for conservative investors
- Revenue normalization from COVID peak is still ongoing — Pfizer must grow non-COVID revenue fast enough to offset continued COVID product volume decline
- Seagen integration at $43B creates significant acquisition cost — integration execution and ADC platform value must justify the premium paid
- LOE (loss of exclusivity) headwinds: Eliquis, Ibrance, and other major Pfizer products face patent cliffs in 2025–2028 requiring continued pipeline execution
- Stelara (formerly $10B+) biosimilar competition beginning 2025 is J&J's primary near-term revenue headwind
- MedTech competitive intensity vs Medtronic, Stryker, and Boston Scientific
- Talc liability litigation (baby powder) remains ongoing legal overhang
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.